Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease

被引：53

作者：

Fox, S

Silverdale, M

Kellett, M

Davies, R

Steiger, M

Fletcher, N

Crossman, A

Brotchie, J

机构：

[1] Walton Ctr Neurol & Neurosurg, Liverpool, Merseyside, England

[2] Univ Manchester, Manchester Movement Disorders Lab, Manchester, Lancs, England

来源：

MOVEMENT DISORDERS | 2004年 / 19卷 / 05期

关键词：

Parkinson's disease; dyskinesia; motor flucations; opioids; naloxone;

D O I：

10.1002/mds.10693

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Opioid peptide transmission is enhanced in the striatum of animal models and Parkinson's disease (PD) patients with levodopa-induced motor complications. Opioid receptor antagonists reduce levodopa-induced dyskinesia in primate models of PD; however, clinical trials to date have been inconclusive. A double-blind, placebo controlled, crossover design study in 14 patients with PD experiencing motor fluctuations was carried out, using the non-subtype-selective opioid receptor antagonist naloxone. Naloxone did not reduce levodopa-induced dyskinesia. The duration of action of levodopa was increased significantly by 17.5%. Non-subtype-selective opioid receptor antagonism may prove useful in the treatment of levodopa-related wearing-off in PD but not in dyskinesia. (C) 2003 Movement Disorder Society.

引用

收藏

页码：554 / 560

页数：7

相关论文

共 48 条

[11] NEOSTRIATAL ENKEPHALIN-IMMUNOREACTIVE NEURONS PROJECT TO THE GLOBUS PALLIDUS [J].

DELFIACCO, M ;

PAXINOS, G ;

CUELLO, AC .

BRAIN RESEARCH, 1982, 231 (01) :1-17

[12] PARTICIPATION OF ENDOGENOUS OPIATES IN REGULATION OF THE HYPOTHALAMIC-PITUITARY-TESTICULAR AXIS IN NORMAL MEN [J].

DELITALA, G ;

GIUSTI, M ;

MAZZOCCHI, G ;

GRANZIERA, L ;

TARDITI, W ;

GIORDANO, G .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1983, 57 (06) :1277-1281

[13] Enhancement of the behavioral response to apomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression [J].

Duty, S ;

Brotchie, JM .

EXPERIMENTAL NEUROLOGY, 1997, 144 (02) :423-432

[14] LEVODOPA REPLACEMENT THERAPY ALTERS ENZYME-ACTIVITIES IN STRIATUM AND NEUROPEPTIDE CONTENT IN STRIATAL OUTPUT REGIONS OF 6-HYDROXYDOPAMINE LESIONED RATS [J].

ENGBER, TM ;

SUSEL, Z ;

KUO, S ;

GERFEN, CR ;

CHASE, TN .

BRAIN RESEARCH, 1991, 552 (01) :113-118

[15] DEGREE AND DURATION OF REVERSAL BY NALOXONE OF EFFECTS OF MORPHINE IN CONSCIOUS SUBJECTS [J].

EVANS, JM ;

HOGG, MIJ ;

LUNN, JN ;

ROSEN, M .

BRITISH MEDICAL JOURNAL, 1974, 2 (5919) :589-591

[16] D1 AND D2 DOPAMINE RECEPTOR REGULATED GENE-EXPRESSION OF STRIATONIGRAL AND STRIATOPALLIDAL NEURONS [J].

GERFEN, CR ;

ENGBER, TM ;

MAHAN, LC ;

SUSEL, Z ;

CHASE, TN ;

MONSMA, FJ ;

SIBLEY, DR .

SCIENCE, 1990, 250 (4986) :1429-1432

[17] DISTRIBUTION OF STRIATONIGRAL AND STRIATOPALLIDAL PEPTIDERGIC NEURONS IN BOTH PATCH AND MATRIX COMPARTMENTS - AN INSITU HYBRIDIZATION HISTOCHEMISTRY AND FLUORESCENT RETROGRADE TRACING STUDY [J].

GERFEN, CR ;

YOUNG, WS .

BRAIN RESEARCH, 1988, 460 (01) :161-167

[18] EFFECT OF NONDOPAMINERGIC DRUGS ON L-DOPA-INDUCED DYSKINESIAS IN MPTP-TREATED MONKEYS [J].

GOMEZMANCILLA, B ;

BEDARD, PJ .

CLINICAL NEUROPHARMACOLOGY, 1993, 16 (05) :418-427

[19] Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease [J].

Henry, B ;

Brotchie, JM .

DRUGS & AGING, 1996, 9 (03) :149-158

[20] Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease [J].

Henry, B ;

Duty, S ;

Fox, SH ;

Crossman, AR ;

Brotchie, JM .

EXPERIMENTAL NEUROLOGY, 2003, 183 (02) :458-468

← 1 2 3 4 5 →